Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner... Int Ophthalmol (2018) 38:923–931 https://doi.org/10.1007/s10792-017-0536-0 ORIGINAL PAPER Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy . . . T. Barth F. Zeman H. Helbig M.-A. Gamulescu Received: 29 December 2016 / Accepted: 10 April 2017 / Published online: 19 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Keywords Choroidal neovascularization  Punctate Purpose To assess the outcome of patients with inner choroidopathy  Intravitreal antiangiogenic choroidal neovascularization (CNV) secondary to therapy  Anti-VEGF (vascular endothelial growth punctate inner choroidopathy (PIC) receiving intrav- factor) itreal anti-VEGF (vascular endothelial growth factor) injections. Methods Sixteen eyes of 16 patients diagnosed with Introduction CNV secondary to PIC were retrospectively assessed. Punctate inner choroidopathy (PIC) is a rare, idio- Results Eleven women and five men with a mean age of 35 years (SD 11, range 16–56 years) received pathic chorioretinopathy that usually affects young and healthy myopic women of Caucasian origin [1, 2]. intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1–9) were given It is defined by the occurrence of multifocal small yellowish white lesions of retinal pigment epithelium per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Ophthalmology Springer Journals

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Loading next page...
 
/lp/springer_journal/intravitreal-anti-vegf-treatment-for-choroidal-neovascularization-lB0j3hYa90
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Ophthalmology
ISSN
0165-5701
eISSN
1573-2630
D.O.I.
10.1007/s10792-017-0536-0
Publisher site
See Article on Publisher Site

Abstract

Int Ophthalmol (2018) 38:923–931 https://doi.org/10.1007/s10792-017-0536-0 ORIGINAL PAPER Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy . . . T. Barth F. Zeman H. Helbig M.-A. Gamulescu Received: 29 December 2016 / Accepted: 10 April 2017 / Published online: 19 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Keywords Choroidal neovascularization  Punctate Purpose To assess the outcome of patients with inner choroidopathy  Intravitreal antiangiogenic choroidal neovascularization (CNV) secondary to therapy  Anti-VEGF (vascular endothelial growth punctate inner choroidopathy (PIC) receiving intrav- factor) itreal anti-VEGF (vascular endothelial growth factor) injections. Methods Sixteen eyes of 16 patients diagnosed with Introduction CNV secondary to PIC were retrospectively assessed. Punctate inner choroidopathy (PIC) is a rare, idio- Results Eleven women and five men with a mean age of 35 years (SD 11, range 16–56 years) received pathic chorioretinopathy that usually affects young and healthy myopic women of Caucasian origin [1, 2]. intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1–9) were given It is defined by the occurrence of multifocal small yellowish white lesions of retinal pigment epithelium per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both

Journal

International OphthalmologySpringer Journals

Published: Apr 19, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off